• Events
    • EURETINA 2023 Amsterdam
      • Information
      • Programme Submission Terms
    • EURETINA 2023 Vilnius (Winter Meeting)
      • Information
      • Programme
      • Registration
      • Hotels
      • Abstracts
    • EURETINA 2022 Hamburg
      • On-Demand Platform (Delegates Only)
      • Sustainability Plan
      • Main Programme
      • Satellite Symposia
      • Exhibitors
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • 2022 Hamburg Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Committees
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • EBO-Euretina Exam
    • Mentorship Programme
    • RMCR Grant Programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
Menu
  • Events
    • EURETINA 2023 Amsterdam
      • Information
      • Programme Submission Terms
    • EURETINA 2023 Vilnius (Winter Meeting)
      • Information
      • Programme
      • Registration
      • Hotels
      • Abstracts
    • EURETINA 2022 Hamburg
      • On-Demand Platform (Delegates Only)
      • Sustainability Plan
      • Main Programme
      • Satellite Symposia
      • Exhibitors
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • 2022 Hamburg Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Committees
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • EBO-Euretina Exam
    • Mentorship Programme
    • RMCR Grant Programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
  • October 17, 2016
  • Author: EURETINA Brief

Established rheumatoid arthritis (RA) drug from AbbVie (adalimumab) shows promise in the treatment of uveitis

An international research collaboration between US and EU clinical investigators, led by Duke University, Durham, North Carolina, has shown that adalimumab, an anti-TNF-α antagonist, marketed by AbbVie Inc. (NYSE: ABBV), may have application in the treatment of active noninfectious intermediate uveitis, posterior uveitis, or panuveitis. The drug, a recombinant DNA-derived human immunoglobulin G1 (IgG1) monoclonal antibody specific for human tumor necrosis factor alpha (TNF-α), is currently approved by the FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis. Results of a randomised phase 3 multicentre trial in uveitis patients has shown that patients treated with adalimumab were less likely to suffer treatment failure than control participants.

 

According to the clinical research group, uveitis has an “estimated incidence of 17 to 52 cases per 100,000 person-years and is estimated to cause 10 to 15% of cases of blindness in Western countries”. Previous research has indicated that pro-inflammatory cytokine tumor necrosis factor α (TNF-α) plays a key role in the inflammation process which characterizes uveitis and that TNF-α levels are up-regulated in the serum and aqueous humor of uveitis patients. In addition, previous uncontrolled case series, retrospective chart reviews and small open-label studies had hinted there may be a beneficial effect in treating patients with chronic or refractory uveitis. To establish more robust evidence for adalimumab, 217 patients were included in an intention-to-treat analyses performed between August 10, 2010, and August 29, 2014.

 

Conducted as a multinational phase 3 trial the study enrolled uveitis patients who were randomly assigned in a 1:1 ratio to receive adalimumab (loading dose of 80 mg followed by a dose of 40 mg every 2 weeks) or a matched placebo. Analysis of the results showed that the median time to treatment failure was 24 weeks for the adalimumab group and 13 weeks for the placebo group. According to the researchers, “among the 217 patients in the intention-to-treat population, those receiving adalimumab were less likely than those in the placebo group to have treatment failure (hazard ratio, 0.50; 95% confidence interval, 0.36 to 0.70; P<0.001).” In addition, the research demonstrated that secondary outcomes including change in anterior chamber cell grade, change in vitreous haze grade, and change in BCVA, were all significantly better in the treatment group. Finally, adverse events, including serious adverse events, were more frequent among adalimumab patients compared to controls (1052.4 vs. 971.7 adverse events and 28.8 vs. 13.6 serious adverse events per 100 person-years). Commenting on the results one of the study authors, Dr. Talin Barisani-Asenbauer MD, PhD stated, “we were able to prospectively demonstrate for the very first time that non-infectious uveitis can also be successfully treated with a cortisol-free medication. That will significantly improve the management of uveitis patients who have only partially responded to corticosteroids, need a corticosteroid sparing therapy or who are unsuitable for treatment with corticosteroids.”

PrevPrevious
NextNext

Meet the Keynote Speakers

Euretina Lecture with Sobha Sivaprasad
Opthalmologica Lecture with Enrico Borrelli
Ophthalmologica Lecture with Enrico Borrelli
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Kreissig Award Lecture with Hiroko Terasaki
Kreissig Award Lecture with Hiroko Terasaki

Secretariat Address
European Society of Retina Specialists
Ground Floor, The Apex Building 
Blackthorn Road
Sandyford Business Park
Co Dublin, D18 H6K2

Phone:+353 1 2100092
Email: [email protected]

EURETINA 2023 Amsterdam

Winter Meeting 2023 Vilnius

EURETINA 2022 Hamburg

Opportunities

Memberships

Forum

About

Privacy Policy

Contact Us

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2022 All rights reserved

  • Events
    • EURETINA 2023 Amsterdam
      • Information
      • Programme Submission Terms
    • EURETINA 2023 Vilnius (Winter Meeting)
      • Information
      • Programme
      • Registration
      • Hotels
      • Abstracts
    • EURETINA 2022 Hamburg
      • On-Demand Platform (Delegates Only)
      • Sustainability Plan
      • Main Programme
      • Satellite Symposia
      • Exhibitors
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • 2022 Hamburg Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Committees
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • EBO-Euretina Exam
    • Mentorship Programme
    • RMCR Grant Programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login